Venture Life Group PLC Appointment of Joint Broker (2296V)
July 20 2018 - 1:00AM
UK Regulatory
TIDMVLG
RNS Number : 2296V
Venture Life Group PLC
20 July 2018
20 July 2018
Venture Life Group plc
(the "VLG or the "Company")
Appointment of Joint Broker
Venture Life Group plc (AIM: VLG), the international consumer
self-care group focused on developing, manufacturing and
commercialising products for the self-care market is pleased to
announce the appointment, with immediate effect, of Cenkos
Securities plc as joint broker, alongside its existing nominated
adviser and joint broker Northland Capital Partners Limited and
Turner Pope Investments Limited.
Contacts
Venture Life Group PLC +44 (0) 1344 742870
Jerry Randall, Chief Executive Officer
Adrian Crockett, Chief Financial Officer
Northland Capital Partners Limited
(Nominated Adviser and Joint Broker) +44 (0) 20 3861 6625
Matthew Johnson / Edward Hutton (Corporate
Finance)
Vadim Alexandre (Corporate Broking)
Cenkos Securities PLC (Joint Broker) +44 (0) 20 7397 8900
Camilla Hume / Mark Connelly (Corporate
Finance)
Michael F Johnson / Russell Kerr (Sales)
Turner Pope Investments (TPI) Ltd (Joint
Broker) +44 (0) 20 3621 4120
James Pope / Ben Turner
Walbrook PR + 44 (0) 20 7933 8780
Anna Dunphy venturelife@walbrookpr.com
+44 (0) 7876 741 001
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company
focused on developing, manufacturing and commercialising products
for the ageing population. The Group's product portfolio includes
some key products such as the UltraDEX oral care products range,
food supplements for lowering cholesterol and maintaining brain
function, medical devices for women's intimate healthcare and
haemorrhoids and dermo-cosmetics for addressing the signs of
ageing.
The products, which are typically recommended by pharmacists or
healthcare practitioners, are available primarily through
pharmacies supplied by the Group's international distribution
partners.
Through its Development & Manufacturing business in Italy,
Biokosmes, the Group also provides development and manufacturing
services to companies in the medical devices and cosmetic
sectors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCVKLFFVDFEBBZ
(END) Dow Jones Newswires
July 20, 2018 02:00 ET (06:00 GMT)
Venture Life (LSE:VLG)
Historical Stock Chart
From Apr 2024 to May 2024
Venture Life (LSE:VLG)
Historical Stock Chart
From May 2023 to May 2024